Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors Clinical Study
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation study of the safety and tolerability of Recombinant
L-IFN adenovirus injection（YSCH-01） when administered via intratumoral injection in patients
with advanced solid tumors. The purpose of this study is to assess the safety and
tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase
1 dose for further study. The study will also evaluate antitumor activity, objective response
rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection